http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 22 Jun 2026 16:04:17 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Pluri+receives+%241.25M+advance+from+chairman-owned+entity/26672939.html <p>Pluri Inc. (NASDAQ: PLUR) entered into an Advance Subscription Agreement on June 14, 2026, with Chutzpah Holdings LP, a limited partnership beneficially owned by Alexandre Weinstein, the chairman of the company's board of directors and an existing shareholder.</p><p>Under the agreement, Chutzpah Holdings agreed to pay Pluri an advance of $1,250,000, which the company received on June 16, 2026. The funds are designated for working capital and general corporate purposes.</p><p>The agreement contemplates that Chutzpah Holdings will participate in a future financing round approved by the board and completed on or before August 14, 2026. The advance amount is expected to be http://www.streetinsider.com/Corporate+News/Pluri+receives+%241.25M+advance+from+chairman-owned+entity/26672939.html Mon, 22 Jun 2026 16:04:17 -0400 PLUR http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Pluri+Inc.++++++++++++++++For%3A+Jun+15/26672894.html si-local-file:///var/storage/secattach/20260622/26672894.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Pluri+Inc.++++++++++++++++For%3A+Jun+15/26672894.html Mon, 22 Jun 2026 16:02:00 -0400 O.31500450 PLUR http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Pluri+Inc.++++++++++++++++For%3A+Jun+15/26672894.html si-local-file:///var/storage/secattach/20260622/26672894.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Pluri+Inc.++++++++++++++++For%3A+Jun+15/26672894.html Mon, 22 Jun 2026 16:02:00 -0400 O.31500450 PLUR http://www.streetinsider.com/Corporate+News/Pluri+subsidiary+Cellav+completes+U.S.+product+listings+for+aesthetic+products/26587480.html <p>Pluri Inc. (NASDAQ: PLUR) announced that its subsidiary Cellav Health and Aesthetics Ltd. has completed U.S. cosmetic product listings for two regenerative aesthetic products, Regenativo+ and Placento+, enabling commercial launch in the United States.</p> <p>The products are now listed under the U.S. cosmetic framework and FDA regulation. Cellav is conducting discussions with U.S. distributors, clinic networks and strategic partners across the United States, United Kingdom and additional international markets.</p> <p>Regenativo+ is a plant-derived treatment, while Placento+ is a placenta-derived formulation. Both products are supplied in Cellav's DUO format consisting of a lyophilized powder vial paired with a booster vial, designed for topical http://www.streetinsider.com/Corporate+News/Pluri+subsidiary+Cellav+completes+U.S.+product+listings+for+aesthetic+products/26587480.html Tue, 02 Jun 2026 07:30:30 -0400 A.06822034 A.50216147 O.06192945 O.20026344 O.31500450 PLUR http://www.streetinsider.com/Corporate+News/Pluri+subsidiary+Cellav+completes+U.S.+product+listings+for+aesthetic+products/26587480.html <p>Pluri Inc. (NASDAQ: PLUR) announced that its subsidiary Cellav Health and Aesthetics Ltd. has completed U.S. cosmetic product listings for two regenerative aesthetic products, Regenativo+ and Placento+, enabling commercial launch in the United States.</p> <p>The products are now listed under the U.S. cosmetic framework and FDA regulation. Cellav is conducting discussions with U.S. distributors, clinic networks and strategic partners across the United States, United Kingdom and additional international markets.</p> <p>Regenativo+ is a plant-derived treatment, while Placento+ is a placenta-derived formulation. Both products are supplied in Cellav's DUO format consisting of a lyophilized powder vial paired with a booster vial, designed for topical http://www.streetinsider.com/Corporate+News/Pluri+subsidiary+Cellav+completes+U.S.+product+listings+for+aesthetic+products/26587480.html Tue, 02 Jun 2026 07:30:30 -0400 A.06822034 A.50216147 O.06192945 O.20026344 O.31500450 PLUR http://www.streetinsider.com/Corporate+News/Pluri+subsidiary+Cellav+completes+U.S.+product+listings+for+aesthetic+products/26587480.html <p>Pluri Inc. (NASDAQ: PLUR) announced that its subsidiary Cellav Health and Aesthetics Ltd. has completed U.S. cosmetic product listings for two regenerative aesthetic products, Regenativo+ and Placento+, enabling commercial launch in the United States.</p> <p>The products are now listed under the U.S. cosmetic framework and FDA regulation. Cellav is conducting discussions with U.S. distributors, clinic networks and strategic partners across the United States, United Kingdom and additional international markets.</p> <p>Regenativo+ is a plant-derived treatment, while Placento+ is a placenta-derived formulation. Both products are supplied in Cellav's DUO format consisting of a lyophilized powder vial paired with a booster vial, designed for topical http://www.streetinsider.com/Corporate+News/Pluri+subsidiary+Cellav+completes+U.S.+product+listings+for+aesthetic+products/26587480.html Tue, 02 Jun 2026 07:30:30 -0400 A.06822034 A.50216147 O.06192945 O.20026344 O.31500450 PLUR http://www.streetinsider.com/Corporate+News/Pluri+subsidiary+Cellav+completes+U.S.+product+listings+for+aesthetic+products/26587480.html <p>Pluri Inc. (NASDAQ: PLUR) announced that its subsidiary Cellav Health and Aesthetics Ltd. has completed U.S. cosmetic product listings for two regenerative aesthetic products, Regenativo+ and Placento+, enabling commercial launch in the United States.</p> <p>The products are now listed under the U.S. cosmetic framework and FDA regulation. Cellav is conducting discussions with U.S. distributors, clinic networks and strategic partners across the United States, United Kingdom and additional international markets.</p> <p>Regenativo+ is a plant-derived treatment, while Placento+ is a placenta-derived formulation. Both products are supplied in Cellav's DUO format consisting of a lyophilized powder vial paired with a booster vial, designed for topical http://www.streetinsider.com/Corporate+News/Pluri+subsidiary+Cellav+completes+U.S.+product+listings+for+aesthetic+products/26587480.html Tue, 02 Jun 2026 07:30:30 -0400 A.06822034 A.50216147 O.06192945 O.20026344 O.31500450 PLUR http://www.streetinsider.com/Corporate+News/Pluri+subsidiary+Cellav+completes+U.S.+product+listings+for+aesthetic+products/26587480.html <p>Pluri Inc. (NASDAQ: PLUR) announced that its subsidiary Cellav Health and Aesthetics Ltd. has completed U.S. cosmetic product listings for two regenerative aesthetic products, Regenativo+ and Placento+, enabling commercial launch in the United States.</p> <p>The products are now listed under the U.S. cosmetic framework and FDA regulation. Cellav is conducting discussions with U.S. distributors, clinic networks and strategic partners across the United States, United Kingdom and additional international markets.</p> <p>Regenativo+ is a plant-derived treatment, while Placento+ is a placenta-derived formulation. Both products are supplied in Cellav's DUO format consisting of a lyophilized powder vial paired with a booster vial, designed for topical http://www.streetinsider.com/Corporate+News/Pluri+subsidiary+Cellav+completes+U.S.+product+listings+for+aesthetic+products/26587480.html Tue, 02 Jun 2026 07:30:30 -0400 A.06822034 A.50216147 O.06192945 O.20026344 O.31500450 PLUR http://www.streetinsider.com/Corporate+News/Pluri+subsidiary+Cellav+completes+U.S.+product+listings+for+aesthetic+products/26587480.html <p>Pluri Inc. (NASDAQ: PLUR) announced that its subsidiary Cellav Health and Aesthetics Ltd. has completed U.S. cosmetic product listings for two regenerative aesthetic products, Regenativo+ and Placento+, enabling commercial launch in the United States.</p> <p>The products are now listed under the U.S. cosmetic framework and FDA regulation. Cellav is conducting discussions with U.S. distributors, clinic networks and strategic partners across the United States, United Kingdom and additional international markets.</p> <p>Regenativo+ is a plant-derived treatment, while Placento+ is a placenta-derived formulation. Both products are supplied in Cellav's DUO format consisting of a lyophilized powder vial paired with a booster vial, designed for topical http://www.streetinsider.com/Corporate+News/Pluri+subsidiary+Cellav+completes+U.S.+product+listings+for+aesthetic+products/26587480.html Tue, 02 Jun 2026 07:30:30 -0400 A.06822034 A.50216147 O.06192945 O.20026344 O.31500450 PLUR http://www.streetinsider.com/Press+Releases/Pluri+Advances+Toward+U.S.+Commercial+Launch+Through+Its+Subsidiary+Cellav%2C+Following+Completion+of+Regenerative+Aesthetic+Products+Listing/26587442.html <p align="center"><strong>Two regenerative aesthetic and longevity products, with clinically validated ingredients</strong><strong>, are</strong><strong> expected to reach the U.S. market during 2026,</strong> <strong>entering a rapidly expanding U.S. medical aesthetics market, projected to reach </strong><a target="_blank" href="https://www.globenewswire.com/Tracker?data=rsSZU8I6FfWdsc-7NWbEmjP0fDuaQp5GWQolfeicHTShQ3DihqYOQIyswCp4R8wypniSkaqu_dDmlBcbKyoLY8zauCXcN5tEfnPvC31XsTfHRSwN5DQjmbTB7MM2zT2JY-XriiB_okHx1xE1y6zSkq4S85t5n_jxPq3L_HER5qg-rXMHwksxY3xA5NxRgAQH3i3XU1P72gfcdA9ypqaLGMddEDfHJqOmPd3wr1lemw85un0K37N33SFstwKhb87B-IuQzGByNgye8tkkzuLCqOFi5mJrWqNvGJQEUVrkcWx2W3nS0N01qTo5klvoGWZMAfiVicvF9UvYCh_4_zx_isERSwnhrFz3BvK67JO3toXaE1FJTqzRkZogyTfFERrkH_H14Qv42JBTyApFlF-io4J9vmAx3i4s6hrkL7P8v--ivT0BJGDehjyua1dc8DDcSshy46xkfk4hrtQETcOfOuIbosGDtYuRLzilNqtjKCENm9B6BVhyvKeOajoKcx7hzZYUZ5wLUTwPLs2W6pS1T8C2F6pZtTR-6yUyzFD_0qJtgKAki0u5BwGfaXbwVGJQjeSdlVkAAWBRpcW7UREeenadJrWOnTrIlIuUc0a0qu4GMMq0Co3an43pgXxb-B7UDKD7m9QR0HyW3Uu8UiGblg9z5UDZKwOUPVwAAwgfNhtThT66od0qxwA3sykqP3L1" rel="nofollow" target="_blank"><strong>$90</strong></a><strong> billion by 2030</strong></p> <p align="justify">HAIFA, Israel, June 02, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=jM8VeXIVTEh27XE4fGWuIfAowcsDLD5V3Rx4ZbfB0DCMv4tLTg6PopPRU3Mfyc4Dfu4IHex_sWd4vsI3IP5fZQ==" rel="nofollow" target="_blank">Pluri Inc</a>. (NASDAQ: PLUR) (TASE: PLUR), a biotechnology company pioneering 3D cell-expansion technology to power scalable cell-based products across therapeutics, regenerative aesthetics, longevity and agri-food tech, today announced that its consumer-health and aesthetics subsidiary, <strong>Cellav Health and Aesthetics Ltd.</strong> (“Cellav”), has completed the development and U.S. cosmetic http://www.streetinsider.com/Press+Releases/Pluri+Advances+Toward+U.S.+Commercial+Launch+Through+Its+Subsidiary+Cellav%2C+Following+Completion+of+Regenerative+Aesthetic+Products+Listing/26587442.html Tue, 02 Jun 2026 07:30:00 -0400 A.06822034 A.50216147 O.06192945 O.20026344 O.31500450 PLUR PLUR http://www.streetinsider.com/Press+Releases/Pluri+Advances+Toward+U.S.+Commercial+Launch+Through+Its+Subsidiary+Cellav%2C+Following+Completion+of+Regenerative+Aesthetic+Products+Listing/26587442.html <p align="center"><strong>Two regenerative aesthetic and longevity products, with clinically validated ingredients</strong><strong>, are</strong><strong> expected to reach the U.S. market during 2026,</strong> <strong>entering a rapidly expanding U.S. medical aesthetics market, projected to reach </strong><a target="_blank" href="https://www.globenewswire.com/Tracker?data=rsSZU8I6FfWdsc-7NWbEmjP0fDuaQp5GWQolfeicHTShQ3DihqYOQIyswCp4R8wypniSkaqu_dDmlBcbKyoLY8zauCXcN5tEfnPvC31XsTfHRSwN5DQjmbTB7MM2zT2JY-XriiB_okHx1xE1y6zSkq4S85t5n_jxPq3L_HER5qg-rXMHwksxY3xA5NxRgAQH3i3XU1P72gfcdA9ypqaLGMddEDfHJqOmPd3wr1lemw85un0K37N33SFstwKhb87B-IuQzGByNgye8tkkzuLCqOFi5mJrWqNvGJQEUVrkcWx2W3nS0N01qTo5klvoGWZMAfiVicvF9UvYCh_4_zx_isERSwnhrFz3BvK67JO3toXaE1FJTqzRkZogyTfFERrkH_H14Qv42JBTyApFlF-io4J9vmAx3i4s6hrkL7P8v--ivT0BJGDehjyua1dc8DDcSshy46xkfk4hrtQETcOfOuIbosGDtYuRLzilNqtjKCENm9B6BVhyvKeOajoKcx7hzZYUZ5wLUTwPLs2W6pS1T8C2F6pZtTR-6yUyzFD_0qJtgKAki0u5BwGfaXbwVGJQjeSdlVkAAWBRpcW7UREeenadJrWOnTrIlIuUc0a0qu4GMMq0Co3an43pgXxb-B7UDKD7m9QR0HyW3Uu8UiGblg9z5UDZKwOUPVwAAwgfNhtThT66od0qxwA3sykqP3L1" rel="nofollow" target="_blank"><strong>$90</strong></a><strong> billion by 2030</strong></p> <p align="justify">HAIFA, Israel, June 02, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=jM8VeXIVTEh27XE4fGWuIfAowcsDLD5V3Rx4ZbfB0DCMv4tLTg6PopPRU3Mfyc4Dfu4IHex_sWd4vsI3IP5fZQ==" rel="nofollow" target="_blank">Pluri Inc</a>. (NASDAQ: PLUR) (TASE: PLUR), a biotechnology company pioneering 3D cell-expansion technology to power scalable cell-based products across therapeutics, regenerative aesthetics, longevity and agri-food tech, today announced that its consumer-health and aesthetics subsidiary, <strong>Cellav Health and Aesthetics Ltd.</strong> (“Cellav”), has completed the development and U.S. cosmetic http://www.streetinsider.com/Press+Releases/Pluri+Advances+Toward+U.S.+Commercial+Launch+Through+Its+Subsidiary+Cellav%2C+Following+Completion+of+Regenerative+Aesthetic+Products+Listing/26587442.html Tue, 02 Jun 2026 07:30:00 -0400 A.06822034 A.50216147 O.06192945 O.20026344 O.31500450 PLUR PLUR http://www.streetinsider.com/Press+Releases/Pluri+Advances+Toward+U.S.+Commercial+Launch+Through+Its+Subsidiary+Cellav%2C+Following+Completion+of+Regenerative+Aesthetic+Products+Listing/26587442.html <p align="center"><strong>Two regenerative aesthetic and longevity products, with clinically validated ingredients</strong><strong>, are</strong><strong> expected to reach the U.S. market during 2026,</strong> <strong>entering a rapidly expanding U.S. medical aesthetics market, projected to reach </strong><a target="_blank" href="https://www.globenewswire.com/Tracker?data=rsSZU8I6FfWdsc-7NWbEmjP0fDuaQp5GWQolfeicHTShQ3DihqYOQIyswCp4R8wypniSkaqu_dDmlBcbKyoLY8zauCXcN5tEfnPvC31XsTfHRSwN5DQjmbTB7MM2zT2JY-XriiB_okHx1xE1y6zSkq4S85t5n_jxPq3L_HER5qg-rXMHwksxY3xA5NxRgAQH3i3XU1P72gfcdA9ypqaLGMddEDfHJqOmPd3wr1lemw85un0K37N33SFstwKhb87B-IuQzGByNgye8tkkzuLCqOFi5mJrWqNvGJQEUVrkcWx2W3nS0N01qTo5klvoGWZMAfiVicvF9UvYCh_4_zx_isERSwnhrFz3BvK67JO3toXaE1FJTqzRkZogyTfFERrkH_H14Qv42JBTyApFlF-io4J9vmAx3i4s6hrkL7P8v--ivT0BJGDehjyua1dc8DDcSshy46xkfk4hrtQETcOfOuIbosGDtYuRLzilNqtjKCENm9B6BVhyvKeOajoKcx7hzZYUZ5wLUTwPLs2W6pS1T8C2F6pZtTR-6yUyzFD_0qJtgKAki0u5BwGfaXbwVGJQjeSdlVkAAWBRpcW7UREeenadJrWOnTrIlIuUc0a0qu4GMMq0Co3an43pgXxb-B7UDKD7m9QR0HyW3Uu8UiGblg9z5UDZKwOUPVwAAwgfNhtThT66od0qxwA3sykqP3L1" rel="nofollow" target="_blank"><strong>$90</strong></a><strong> billion by 2030</strong></p> <p align="justify">HAIFA, Israel, June 02, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=jM8VeXIVTEh27XE4fGWuIfAowcsDLD5V3Rx4ZbfB0DCMv4tLTg6PopPRU3Mfyc4Dfu4IHex_sWd4vsI3IP5fZQ==" rel="nofollow" target="_blank">Pluri Inc</a>. (NASDAQ: PLUR) (TASE: PLUR), a biotechnology company pioneering 3D cell-expansion technology to power scalable cell-based products across therapeutics, regenerative aesthetics, longevity and agri-food tech, today announced that its consumer-health and aesthetics subsidiary, <strong>Cellav Health and Aesthetics Ltd.</strong> (“Cellav”), has completed the development and U.S. cosmetic http://www.streetinsider.com/Press+Releases/Pluri+Advances+Toward+U.S.+Commercial+Launch+Through+Its+Subsidiary+Cellav%2C+Following+Completion+of+Regenerative+Aesthetic+Products+Listing/26587442.html Tue, 02 Jun 2026 07:30:00 -0400 A.06822034 A.50216147 O.06192945 O.20026344 O.31500450 PLUR PLUR http://www.streetinsider.com/Press+Releases/Pluri+Advances+Toward+U.S.+Commercial+Launch+Through+Its+Subsidiary+Cellav%2C+Following+Completion+of+Regenerative+Aesthetic+Products+Listing/26587442.html <p align="center"><strong>Two regenerative aesthetic and longevity products, with clinically validated ingredients</strong><strong>, are</strong><strong> expected to reach the U.S. market during 2026,</strong> <strong>entering a rapidly expanding U.S. medical aesthetics market, projected to reach </strong><a target="_blank" href="https://www.globenewswire.com/Tracker?data=rsSZU8I6FfWdsc-7NWbEmjP0fDuaQp5GWQolfeicHTShQ3DihqYOQIyswCp4R8wypniSkaqu_dDmlBcbKyoLY8zauCXcN5tEfnPvC31XsTfHRSwN5DQjmbTB7MM2zT2JY-XriiB_okHx1xE1y6zSkq4S85t5n_jxPq3L_HER5qg-rXMHwksxY3xA5NxRgAQH3i3XU1P72gfcdA9ypqaLGMddEDfHJqOmPd3wr1lemw85un0K37N33SFstwKhb87B-IuQzGByNgye8tkkzuLCqOFi5mJrWqNvGJQEUVrkcWx2W3nS0N01qTo5klvoGWZMAfiVicvF9UvYCh_4_zx_isERSwnhrFz3BvK67JO3toXaE1FJTqzRkZogyTfFERrkH_H14Qv42JBTyApFlF-io4J9vmAx3i4s6hrkL7P8v--ivT0BJGDehjyua1dc8DDcSshy46xkfk4hrtQETcOfOuIbosGDtYuRLzilNqtjKCENm9B6BVhyvKeOajoKcx7hzZYUZ5wLUTwPLs2W6pS1T8C2F6pZtTR-6yUyzFD_0qJtgKAki0u5BwGfaXbwVGJQjeSdlVkAAWBRpcW7UREeenadJrWOnTrIlIuUc0a0qu4GMMq0Co3an43pgXxb-B7UDKD7m9QR0HyW3Uu8UiGblg9z5UDZKwOUPVwAAwgfNhtThT66od0qxwA3sykqP3L1" rel="nofollow" target="_blank"><strong>$90</strong></a><strong> billion by 2030</strong></p> <p align="justify">HAIFA, Israel, June 02, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=jM8VeXIVTEh27XE4fGWuIfAowcsDLD5V3Rx4ZbfB0DCMv4tLTg6PopPRU3Mfyc4Dfu4IHex_sWd4vsI3IP5fZQ==" rel="nofollow" target="_blank">Pluri Inc</a>. (NASDAQ: PLUR) (TASE: PLUR), a biotechnology company pioneering 3D cell-expansion technology to power scalable cell-based products across therapeutics, regenerative aesthetics, longevity and agri-food tech, today announced that its consumer-health and aesthetics subsidiary, <strong>Cellav Health and Aesthetics Ltd.</strong> (“Cellav”), has completed the development and U.S. cosmetic http://www.streetinsider.com/Press+Releases/Pluri+Advances+Toward+U.S.+Commercial+Launch+Through+Its+Subsidiary+Cellav%2C+Following+Completion+of+Regenerative+Aesthetic+Products+Listing/26587442.html Tue, 02 Jun 2026 07:30:00 -0400 A.06822034 A.50216147 O.06192945 O.20026344 O.31500450 PLUR PLUR http://www.streetinsider.com/Press+Releases/Pluri+Advances+Toward+U.S.+Commercial+Launch+Through+Its+Subsidiary+Cellav%2C+Following+Completion+of+Regenerative+Aesthetic+Products+Listing/26587442.html <p align="center"><strong>Two regenerative aesthetic and longevity products, with clinically validated ingredients</strong><strong>, are</strong><strong> expected to reach the U.S. market during 2026,</strong> <strong>entering a rapidly expanding U.S. medical aesthetics market, projected to reach </strong><a target="_blank" href="https://www.globenewswire.com/Tracker?data=rsSZU8I6FfWdsc-7NWbEmjP0fDuaQp5GWQolfeicHTShQ3DihqYOQIyswCp4R8wypniSkaqu_dDmlBcbKyoLY8zauCXcN5tEfnPvC31XsTfHRSwN5DQjmbTB7MM2zT2JY-XriiB_okHx1xE1y6zSkq4S85t5n_jxPq3L_HER5qg-rXMHwksxY3xA5NxRgAQH3i3XU1P72gfcdA9ypqaLGMddEDfHJqOmPd3wr1lemw85un0K37N33SFstwKhb87B-IuQzGByNgye8tkkzuLCqOFi5mJrWqNvGJQEUVrkcWx2W3nS0N01qTo5klvoGWZMAfiVicvF9UvYCh_4_zx_isERSwnhrFz3BvK67JO3toXaE1FJTqzRkZogyTfFERrkH_H14Qv42JBTyApFlF-io4J9vmAx3i4s6hrkL7P8v--ivT0BJGDehjyua1dc8DDcSshy46xkfk4hrtQETcOfOuIbosGDtYuRLzilNqtjKCENm9B6BVhyvKeOajoKcx7hzZYUZ5wLUTwPLs2W6pS1T8C2F6pZtTR-6yUyzFD_0qJtgKAki0u5BwGfaXbwVGJQjeSdlVkAAWBRpcW7UREeenadJrWOnTrIlIuUc0a0qu4GMMq0Co3an43pgXxb-B7UDKD7m9QR0HyW3Uu8UiGblg9z5UDZKwOUPVwAAwgfNhtThT66od0qxwA3sykqP3L1" rel="nofollow" target="_blank"><strong>$90</strong></a><strong> billion by 2030</strong></p> <p align="justify">HAIFA, Israel, June 02, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=jM8VeXIVTEh27XE4fGWuIfAowcsDLD5V3Rx4ZbfB0DCMv4tLTg6PopPRU3Mfyc4Dfu4IHex_sWd4vsI3IP5fZQ==" rel="nofollow" target="_blank">Pluri Inc</a>. (NASDAQ: PLUR) (TASE: PLUR), a biotechnology company pioneering 3D cell-expansion technology to power scalable cell-based products across therapeutics, regenerative aesthetics, longevity and agri-food tech, today announced that its consumer-health and aesthetics subsidiary, <strong>Cellav Health and Aesthetics Ltd.</strong> (“Cellav”), has completed the development and U.S. cosmetic http://www.streetinsider.com/Press+Releases/Pluri+Advances+Toward+U.S.+Commercial+Launch+Through+Its+Subsidiary+Cellav%2C+Following+Completion+of+Regenerative+Aesthetic+Products+Listing/26587442.html Tue, 02 Jun 2026 07:30:00 -0400 A.06822034 A.50216147 O.06192945 O.20026344 O.31500450 PLUR PLUR http://www.streetinsider.com/Press+Releases/Pluri+Advances+Toward+U.S.+Commercial+Launch+Through+Its+Subsidiary+Cellav%2C+Following+Completion+of+Regenerative+Aesthetic+Products+Listing/26587442.html <p align="center"><strong>Two regenerative aesthetic and longevity products, with clinically validated ingredients</strong><strong>, are</strong><strong> expected to reach the U.S. market during 2026,</strong> <strong>entering a rapidly expanding U.S. medical aesthetics market, projected to reach </strong><a target="_blank" href="https://www.globenewswire.com/Tracker?data=rsSZU8I6FfWdsc-7NWbEmjP0fDuaQp5GWQolfeicHTShQ3DihqYOQIyswCp4R8wypniSkaqu_dDmlBcbKyoLY8zauCXcN5tEfnPvC31XsTfHRSwN5DQjmbTB7MM2zT2JY-XriiB_okHx1xE1y6zSkq4S85t5n_jxPq3L_HER5qg-rXMHwksxY3xA5NxRgAQH3i3XU1P72gfcdA9ypqaLGMddEDfHJqOmPd3wr1lemw85un0K37N33SFstwKhb87B-IuQzGByNgye8tkkzuLCqOFi5mJrWqNvGJQEUVrkcWx2W3nS0N01qTo5klvoGWZMAfiVicvF9UvYCh_4_zx_isERSwnhrFz3BvK67JO3toXaE1FJTqzRkZogyTfFERrkH_H14Qv42JBTyApFlF-io4J9vmAx3i4s6hrkL7P8v--ivT0BJGDehjyua1dc8DDcSshy46xkfk4hrtQETcOfOuIbosGDtYuRLzilNqtjKCENm9B6BVhyvKeOajoKcx7hzZYUZ5wLUTwPLs2W6pS1T8C2F6pZtTR-6yUyzFD_0qJtgKAki0u5BwGfaXbwVGJQjeSdlVkAAWBRpcW7UREeenadJrWOnTrIlIuUc0a0qu4GMMq0Co3an43pgXxb-B7UDKD7m9QR0HyW3Uu8UiGblg9z5UDZKwOUPVwAAwgfNhtThT66od0qxwA3sykqP3L1" rel="nofollow" target="_blank"><strong>$90</strong></a><strong> billion by 2030</strong></p> <p align="justify">HAIFA, Israel, June 02, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=jM8VeXIVTEh27XE4fGWuIfAowcsDLD5V3Rx4ZbfB0DCMv4tLTg6PopPRU3Mfyc4Dfu4IHex_sWd4vsI3IP5fZQ==" rel="nofollow" target="_blank">Pluri Inc</a>. (NASDAQ: PLUR) (TASE: PLUR), a biotechnology company pioneering 3D cell-expansion technology to power scalable cell-based products across therapeutics, regenerative aesthetics, longevity and agri-food tech, today announced that its consumer-health and aesthetics subsidiary, <strong>Cellav Health and Aesthetics Ltd.</strong> (“Cellav”), has completed the development and U.S. cosmetic http://www.streetinsider.com/Press+Releases/Pluri+Advances+Toward+U.S.+Commercial+Launch+Through+Its+Subsidiary+Cellav%2C+Following+Completion+of+Regenerative+Aesthetic+Products+Listing/26587442.html Tue, 02 Jun 2026 07:30:00 -0400 A.06822034 A.50216147 O.06192945 O.20026344 O.31500450 PLUR PLUR http://www.streetinsider.com/Press+Releases/Pluri+Advances+Toward+U.S.+Commercial+Launch+Through+Its+Subsidiary+Cellav%2C+Following+Completion+of+Regenerative+Aesthetic+Products+Listing/26587442.html <p align="center"><strong>Two regenerative aesthetic and longevity products, with clinically validated ingredients</strong><strong>, are</strong><strong> expected to reach the U.S. market during 2026,</strong> <strong>entering a rapidly expanding U.S. medical aesthetics market, projected to reach </strong><a target="_blank" href="https://www.globenewswire.com/Tracker?data=rsSZU8I6FfWdsc-7NWbEmjP0fDuaQp5GWQolfeicHTShQ3DihqYOQIyswCp4R8wypniSkaqu_dDmlBcbKyoLY8zauCXcN5tEfnPvC31XsTfHRSwN5DQjmbTB7MM2zT2JY-XriiB_okHx1xE1y6zSkq4S85t5n_jxPq3L_HER5qg-rXMHwksxY3xA5NxRgAQH3i3XU1P72gfcdA9ypqaLGMddEDfHJqOmPd3wr1lemw85un0K37N33SFstwKhb87B-IuQzGByNgye8tkkzuLCqOFi5mJrWqNvGJQEUVrkcWx2W3nS0N01qTo5klvoGWZMAfiVicvF9UvYCh_4_zx_isERSwnhrFz3BvK67JO3toXaE1FJTqzRkZogyTfFERrkH_H14Qv42JBTyApFlF-io4J9vmAx3i4s6hrkL7P8v--ivT0BJGDehjyua1dc8DDcSshy46xkfk4hrtQETcOfOuIbosGDtYuRLzilNqtjKCENm9B6BVhyvKeOajoKcx7hzZYUZ5wLUTwPLs2W6pS1T8C2F6pZtTR-6yUyzFD_0qJtgKAki0u5BwGfaXbwVGJQjeSdlVkAAWBRpcW7UREeenadJrWOnTrIlIuUc0a0qu4GMMq0Co3an43pgXxb-B7UDKD7m9QR0HyW3Uu8UiGblg9z5UDZKwOUPVwAAwgfNhtThT66od0qxwA3sykqP3L1" rel="nofollow" target="_blank"><strong>$90</strong></a><strong> billion by 2030</strong></p> <p align="justify">HAIFA, Israel, June 02, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=jM8VeXIVTEh27XE4fGWuIfAowcsDLD5V3Rx4ZbfB0DCMv4tLTg6PopPRU3Mfyc4Dfu4IHex_sWd4vsI3IP5fZQ==" rel="nofollow" target="_blank">Pluri Inc</a>. (NASDAQ: PLUR) (TASE: PLUR), a biotechnology company pioneering 3D cell-expansion technology to power scalable cell-based products across therapeutics, regenerative aesthetics, longevity and agri-food tech, today announced that its consumer-health and aesthetics subsidiary, <strong>Cellav Health and Aesthetics Ltd.</strong> (“Cellav”), has completed the development and U.S. cosmetic http://www.streetinsider.com/Press+Releases/Pluri+Advances+Toward+U.S.+Commercial+Launch+Through+Its+Subsidiary+Cellav%2C+Following+Completion+of+Regenerative+Aesthetic+Products+Listing/26587442.html Tue, 02 Jun 2026 07:30:00 -0400 A.06822034 A.50216147 O.06192945 O.20026344 O.31500450 PLUR PLUR http://www.streetinsider.com/Globe+Newswire/Pluri+Advances+Toward+U.S.+Commercial+Launch+Through+Its+Subsidiary+Cellav%2C+Following+Completion+of+Regenerative+Aesthetic+Products+Listing/26587442.html <p align="center"><strong>Two regenerative aesthetic and longevity products, with clinically validated ingredients</strong><strong>, are</strong><strong> expected to reach the U.S. market during 2026,</strong> <strong>entering a rapidly expanding U.S. medical aesthetics market, projected to reach </strong><a target="_blank" href="https://www.globenewswire.com/Tracker?data=rsSZU8I6FfWdsc-7NWbEmjP0fDuaQp5GWQolfeicHTShQ3DihqYOQIyswCp4R8wypniSkaqu_dDmlBcbKyoLY8zauCXcN5tEfnPvC31XsTfHRSwN5DQjmbTB7MM2zT2JY-XriiB_okHx1xE1y6zSkq4S85t5n_jxPq3L_HER5qg-rXMHwksxY3xA5NxRgAQH3i3XU1P72gfcdA9ypqaLGMddEDfHJqOmPd3wr1lemw85un0K37N33SFstwKhb87B-IuQzGByNgye8tkkzuLCqOFi5mJrWqNvGJQEUVrkcWx2W3nS0N01qTo5klvoGWZMAfiVicvF9UvYCh_4_zx_isERSwnhrFz3BvK67JO3toXaE1FJTqzRkZogyTfFERrkH_H14Qv42JBTyApFlF-io4J9vmAx3i4s6hrkL7P8v--ivT0BJGDehjyua1dc8DDcSshy46xkfk4hrtQETcOfOuIbosGDtYuRLzilNqtjKCENm9B6BVhyvKeOajoKcx7hzZYUZ5wLUTwPLs2W6pS1T8C2F6pZtTR-6yUyzFD_0qJtgKAki0u5BwGfaXbwVGJQjeSdlVkAAWBRpcW7UREeenadJrWOnTrIlIuUc0a0qu4GMMq0Co3an43pgXxb-B7UDKD7m9QR0HyW3Uu8UiGblg9z5UDZKwOUPVwAAwgfNhtThT66od0qxwA3sykqP3L1" rel="nofollow" target="_blank"><strong>$90</strong></a><strong> billion by 2030</strong></p> <p align="justify">HAIFA, Israel, June 02, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=jM8VeXIVTEh27XE4fGWuIfAowcsDLD5V3Rx4ZbfB0DCMv4tLTg6PopPRU3Mfyc4Dfu4IHex_sWd4vsI3IP5fZQ==" rel="nofollow" target="_blank">Pluri Inc</a>. (NASDAQ: PLUR) (TASE: PLUR), a biotechnology company pioneering 3D cell-expansion technology to power scalable cell-based products across therapeutics, regenerative aesthetics, longevity and agri-food tech, today announced that its consumer-health and aesthetics subsidiary, <strong>Cellav Health and Aesthetics Ltd.</strong> (“Cellav”), has completed the development and U.S. cosmetic http://www.streetinsider.com/Globe+Newswire/Pluri+Advances+Toward+U.S.+Commercial+Launch+Through+Its+Subsidiary+Cellav%2C+Following+Completion+of+Regenerative+Aesthetic+Products+Listing/26587442.html Tue, 02 Jun 2026 07:30:00 -0400 A.06822034 A.50216147 O.06192945 O.20026344 O.31500450 PLUR PLUR http://www.streetinsider.com/Globe+Newswire/Pluri+Advances+Toward+U.S.+Commercial+Launch+Through+Its+Subsidiary+Cellav%2C+Following+Completion+of+Regenerative+Aesthetic+Products+Listing/26587442.html <p align="center"><strong>Two regenerative aesthetic and longevity products, with clinically validated ingredients</strong><strong>, are</strong><strong> expected to reach the U.S. market during 2026,</strong> <strong>entering a rapidly expanding U.S. medical aesthetics market, projected to reach </strong><a target="_blank" href="https://www.globenewswire.com/Tracker?data=rsSZU8I6FfWdsc-7NWbEmjP0fDuaQp5GWQolfeicHTShQ3DihqYOQIyswCp4R8wypniSkaqu_dDmlBcbKyoLY8zauCXcN5tEfnPvC31XsTfHRSwN5DQjmbTB7MM2zT2JY-XriiB_okHx1xE1y6zSkq4S85t5n_jxPq3L_HER5qg-rXMHwksxY3xA5NxRgAQH3i3XU1P72gfcdA9ypqaLGMddEDfHJqOmPd3wr1lemw85un0K37N33SFstwKhb87B-IuQzGByNgye8tkkzuLCqOFi5mJrWqNvGJQEUVrkcWx2W3nS0N01qTo5klvoGWZMAfiVicvF9UvYCh_4_zx_isERSwnhrFz3BvK67JO3toXaE1FJTqzRkZogyTfFERrkH_H14Qv42JBTyApFlF-io4J9vmAx3i4s6hrkL7P8v--ivT0BJGDehjyua1dc8DDcSshy46xkfk4hrtQETcOfOuIbosGDtYuRLzilNqtjKCENm9B6BVhyvKeOajoKcx7hzZYUZ5wLUTwPLs2W6pS1T8C2F6pZtTR-6yUyzFD_0qJtgKAki0u5BwGfaXbwVGJQjeSdlVkAAWBRpcW7UREeenadJrWOnTrIlIuUc0a0qu4GMMq0Co3an43pgXxb-B7UDKD7m9QR0HyW3Uu8UiGblg9z5UDZKwOUPVwAAwgfNhtThT66od0qxwA3sykqP3L1" rel="nofollow" target="_blank"><strong>$90</strong></a><strong> billion by 2030</strong></p> <p align="justify">HAIFA, Israel, June 02, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=jM8VeXIVTEh27XE4fGWuIfAowcsDLD5V3Rx4ZbfB0DCMv4tLTg6PopPRU3Mfyc4Dfu4IHex_sWd4vsI3IP5fZQ==" rel="nofollow" target="_blank">Pluri Inc</a>. (NASDAQ: PLUR) (TASE: PLUR), a biotechnology company pioneering 3D cell-expansion technology to power scalable cell-based products across therapeutics, regenerative aesthetics, longevity and agri-food tech, today announced that its consumer-health and aesthetics subsidiary, <strong>Cellav Health and Aesthetics Ltd.</strong> (“Cellav”), has completed the development and U.S. cosmetic http://www.streetinsider.com/Globe+Newswire/Pluri+Advances+Toward+U.S.+Commercial+Launch+Through+Its+Subsidiary+Cellav%2C+Following+Completion+of+Regenerative+Aesthetic+Products+Listing/26587442.html Tue, 02 Jun 2026 07:30:00 -0400 A.06822034 A.50216147 O.06192945 O.20026344 O.31500450 PLUR PLUR http://www.streetinsider.com/Globe+Newswire/Pluri+Advances+Toward+U.S.+Commercial+Launch+Through+Its+Subsidiary+Cellav%2C+Following+Completion+of+Regenerative+Aesthetic+Products+Listing/26587442.html <p align="center"><strong>Two regenerative aesthetic and longevity products, with clinically validated ingredients</strong><strong>, are</strong><strong> expected to reach the U.S. market during 2026,</strong> <strong>entering a rapidly expanding U.S. medical aesthetics market, projected to reach </strong><a target="_blank" href="https://www.globenewswire.com/Tracker?data=rsSZU8I6FfWdsc-7NWbEmjP0fDuaQp5GWQolfeicHTShQ3DihqYOQIyswCp4R8wypniSkaqu_dDmlBcbKyoLY8zauCXcN5tEfnPvC31XsTfHRSwN5DQjmbTB7MM2zT2JY-XriiB_okHx1xE1y6zSkq4S85t5n_jxPq3L_HER5qg-rXMHwksxY3xA5NxRgAQH3i3XU1P72gfcdA9ypqaLGMddEDfHJqOmPd3wr1lemw85un0K37N33SFstwKhb87B-IuQzGByNgye8tkkzuLCqOFi5mJrWqNvGJQEUVrkcWx2W3nS0N01qTo5klvoGWZMAfiVicvF9UvYCh_4_zx_isERSwnhrFz3BvK67JO3toXaE1FJTqzRkZogyTfFERrkH_H14Qv42JBTyApFlF-io4J9vmAx3i4s6hrkL7P8v--ivT0BJGDehjyua1dc8DDcSshy46xkfk4hrtQETcOfOuIbosGDtYuRLzilNqtjKCENm9B6BVhyvKeOajoKcx7hzZYUZ5wLUTwPLs2W6pS1T8C2F6pZtTR-6yUyzFD_0qJtgKAki0u5BwGfaXbwVGJQjeSdlVkAAWBRpcW7UREeenadJrWOnTrIlIuUc0a0qu4GMMq0Co3an43pgXxb-B7UDKD7m9QR0HyW3Uu8UiGblg9z5UDZKwOUPVwAAwgfNhtThT66od0qxwA3sykqP3L1" rel="nofollow" target="_blank"><strong>$90</strong></a><strong> billion by 2030</strong></p> <p align="justify">HAIFA, Israel, June 02, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=jM8VeXIVTEh27XE4fGWuIfAowcsDLD5V3Rx4ZbfB0DCMv4tLTg6PopPRU3Mfyc4Dfu4IHex_sWd4vsI3IP5fZQ==" rel="nofollow" target="_blank">Pluri Inc</a>. (NASDAQ: PLUR) (TASE: PLUR), a biotechnology company pioneering 3D cell-expansion technology to power scalable cell-based products across therapeutics, regenerative aesthetics, longevity and agri-food tech, today announced that its consumer-health and aesthetics subsidiary, <strong>Cellav Health and Aesthetics Ltd.</strong> (“Cellav”), has completed the development and U.S. cosmetic http://www.streetinsider.com/Globe+Newswire/Pluri+Advances+Toward+U.S.+Commercial+Launch+Through+Its+Subsidiary+Cellav%2C+Following+Completion+of+Regenerative+Aesthetic+Products+Listing/26587442.html Tue, 02 Jun 2026 07:30:00 -0400 A.06822034 A.50216147 O.06192945 O.20026344 O.31500450 PLUR PLUR http://www.streetinsider.com/Globe+Newswire/Pluri+Advances+Toward+U.S.+Commercial+Launch+Through+Its+Subsidiary+Cellav%2C+Following+Completion+of+Regenerative+Aesthetic+Products+Listing/26587442.html <p align="center"><strong>Two regenerative aesthetic and longevity products, with clinically validated ingredients</strong><strong>, are</strong><strong> expected to reach the U.S. market during 2026,</strong> <strong>entering a rapidly expanding U.S. medical aesthetics market, projected to reach </strong><a target="_blank" href="https://www.globenewswire.com/Tracker?data=rsSZU8I6FfWdsc-7NWbEmjP0fDuaQp5GWQolfeicHTShQ3DihqYOQIyswCp4R8wypniSkaqu_dDmlBcbKyoLY8zauCXcN5tEfnPvC31XsTfHRSwN5DQjmbTB7MM2zT2JY-XriiB_okHx1xE1y6zSkq4S85t5n_jxPq3L_HER5qg-rXMHwksxY3xA5NxRgAQH3i3XU1P72gfcdA9ypqaLGMddEDfHJqOmPd3wr1lemw85un0K37N33SFstwKhb87B-IuQzGByNgye8tkkzuLCqOFi5mJrWqNvGJQEUVrkcWx2W3nS0N01qTo5klvoGWZMAfiVicvF9UvYCh_4_zx_isERSwnhrFz3BvK67JO3toXaE1FJTqzRkZogyTfFERrkH_H14Qv42JBTyApFlF-io4J9vmAx3i4s6hrkL7P8v--ivT0BJGDehjyua1dc8DDcSshy46xkfk4hrtQETcOfOuIbosGDtYuRLzilNqtjKCENm9B6BVhyvKeOajoKcx7hzZYUZ5wLUTwPLs2W6pS1T8C2F6pZtTR-6yUyzFD_0qJtgKAki0u5BwGfaXbwVGJQjeSdlVkAAWBRpcW7UREeenadJrWOnTrIlIuUc0a0qu4GMMq0Co3an43pgXxb-B7UDKD7m9QR0HyW3Uu8UiGblg9z5UDZKwOUPVwAAwgfNhtThT66od0qxwA3sykqP3L1" rel="nofollow" target="_blank"><strong>$90</strong></a><strong> billion by 2030</strong></p> <p align="justify">HAIFA, Israel, June 02, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=jM8VeXIVTEh27XE4fGWuIfAowcsDLD5V3Rx4ZbfB0DCMv4tLTg6PopPRU3Mfyc4Dfu4IHex_sWd4vsI3IP5fZQ==" rel="nofollow" target="_blank">Pluri Inc</a>. (NASDAQ: PLUR) (TASE: PLUR), a biotechnology company pioneering 3D cell-expansion technology to power scalable cell-based products across therapeutics, regenerative aesthetics, longevity and agri-food tech, today announced that its consumer-health and aesthetics subsidiary, <strong>Cellav Health and Aesthetics Ltd.</strong> (“Cellav”), has completed the development and U.S. cosmetic http://www.streetinsider.com/Globe+Newswire/Pluri+Advances+Toward+U.S.+Commercial+Launch+Through+Its+Subsidiary+Cellav%2C+Following+Completion+of+Regenerative+Aesthetic+Products+Listing/26587442.html Tue, 02 Jun 2026 07:30:00 -0400 A.06822034 A.50216147 O.06192945 O.20026344 O.31500450 PLUR PLUR http://www.streetinsider.com/Globe+Newswire/Pluri+Advances+Toward+U.S.+Commercial+Launch+Through+Its+Subsidiary+Cellav%2C+Following+Completion+of+Regenerative+Aesthetic+Products+Listing/26587442.html <p align="center"><strong>Two regenerative aesthetic and longevity products, with clinically validated ingredients</strong><strong>, are</strong><strong> expected to reach the U.S. market during 2026,</strong> <strong>entering a rapidly expanding U.S. medical aesthetics market, projected to reach </strong><a target="_blank" href="https://www.globenewswire.com/Tracker?data=rsSZU8I6FfWdsc-7NWbEmjP0fDuaQp5GWQolfeicHTShQ3DihqYOQIyswCp4R8wypniSkaqu_dDmlBcbKyoLY8zauCXcN5tEfnPvC31XsTfHRSwN5DQjmbTB7MM2zT2JY-XriiB_okHx1xE1y6zSkq4S85t5n_jxPq3L_HER5qg-rXMHwksxY3xA5NxRgAQH3i3XU1P72gfcdA9ypqaLGMddEDfHJqOmPd3wr1lemw85un0K37N33SFstwKhb87B-IuQzGByNgye8tkkzuLCqOFi5mJrWqNvGJQEUVrkcWx2W3nS0N01qTo5klvoGWZMAfiVicvF9UvYCh_4_zx_isERSwnhrFz3BvK67JO3toXaE1FJTqzRkZogyTfFERrkH_H14Qv42JBTyApFlF-io4J9vmAx3i4s6hrkL7P8v--ivT0BJGDehjyua1dc8DDcSshy46xkfk4hrtQETcOfOuIbosGDtYuRLzilNqtjKCENm9B6BVhyvKeOajoKcx7hzZYUZ5wLUTwPLs2W6pS1T8C2F6pZtTR-6yUyzFD_0qJtgKAki0u5BwGfaXbwVGJQjeSdlVkAAWBRpcW7UREeenadJrWOnTrIlIuUc0a0qu4GMMq0Co3an43pgXxb-B7UDKD7m9QR0HyW3Uu8UiGblg9z5UDZKwOUPVwAAwgfNhtThT66od0qxwA3sykqP3L1" rel="nofollow" target="_blank"><strong>$90</strong></a><strong> billion by 2030</strong></p> <p align="justify">HAIFA, Israel, June 02, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=jM8VeXIVTEh27XE4fGWuIfAowcsDLD5V3Rx4ZbfB0DCMv4tLTg6PopPRU3Mfyc4Dfu4IHex_sWd4vsI3IP5fZQ==" rel="nofollow" target="_blank">Pluri Inc</a>. (NASDAQ: PLUR) (TASE: PLUR), a biotechnology company pioneering 3D cell-expansion technology to power scalable cell-based products across therapeutics, regenerative aesthetics, longevity and agri-food tech, today announced that its consumer-health and aesthetics subsidiary, <strong>Cellav Health and Aesthetics Ltd.</strong> (“Cellav”), has completed the development and U.S. cosmetic http://www.streetinsider.com/Globe+Newswire/Pluri+Advances+Toward+U.S.+Commercial+Launch+Through+Its+Subsidiary+Cellav%2C+Following+Completion+of+Regenerative+Aesthetic+Products+Listing/26587442.html Tue, 02 Jun 2026 07:30:00 -0400 A.06822034 A.50216147 O.06192945 O.20026344 O.31500450 PLUR PLUR http://www.streetinsider.com/Globe+Newswire/Pluri+Advances+Toward+U.S.+Commercial+Launch+Through+Its+Subsidiary+Cellav%2C+Following+Completion+of+Regenerative+Aesthetic+Products+Listing/26587442.html <p align="center"><strong>Two regenerative aesthetic and longevity products, with clinically validated ingredients</strong><strong>, are</strong><strong> expected to reach the U.S. market during 2026,</strong> <strong>entering a rapidly expanding U.S. medical aesthetics market, projected to reach </strong><a target="_blank" href="https://www.globenewswire.com/Tracker?data=rsSZU8I6FfWdsc-7NWbEmjP0fDuaQp5GWQolfeicHTShQ3DihqYOQIyswCp4R8wypniSkaqu_dDmlBcbKyoLY8zauCXcN5tEfnPvC31XsTfHRSwN5DQjmbTB7MM2zT2JY-XriiB_okHx1xE1y6zSkq4S85t5n_jxPq3L_HER5qg-rXMHwksxY3xA5NxRgAQH3i3XU1P72gfcdA9ypqaLGMddEDfHJqOmPd3wr1lemw85un0K37N33SFstwKhb87B-IuQzGByNgye8tkkzuLCqOFi5mJrWqNvGJQEUVrkcWx2W3nS0N01qTo5klvoGWZMAfiVicvF9UvYCh_4_zx_isERSwnhrFz3BvK67JO3toXaE1FJTqzRkZogyTfFERrkH_H14Qv42JBTyApFlF-io4J9vmAx3i4s6hrkL7P8v--ivT0BJGDehjyua1dc8DDcSshy46xkfk4hrtQETcOfOuIbosGDtYuRLzilNqtjKCENm9B6BVhyvKeOajoKcx7hzZYUZ5wLUTwPLs2W6pS1T8C2F6pZtTR-6yUyzFD_0qJtgKAki0u5BwGfaXbwVGJQjeSdlVkAAWBRpcW7UREeenadJrWOnTrIlIuUc0a0qu4GMMq0Co3an43pgXxb-B7UDKD7m9QR0HyW3Uu8UiGblg9z5UDZKwOUPVwAAwgfNhtThT66od0qxwA3sykqP3L1" rel="nofollow" target="_blank"><strong>$90</strong></a><strong> billion by 2030</strong></p> <p align="justify">HAIFA, Israel, June 02, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=jM8VeXIVTEh27XE4fGWuIfAowcsDLD5V3Rx4ZbfB0DCMv4tLTg6PopPRU3Mfyc4Dfu4IHex_sWd4vsI3IP5fZQ==" rel="nofollow" target="_blank">Pluri Inc</a>. (NASDAQ: PLUR) (TASE: PLUR), a biotechnology company pioneering 3D cell-expansion technology to power scalable cell-based products across therapeutics, regenerative aesthetics, longevity and agri-food tech, today announced that its consumer-health and aesthetics subsidiary, <strong>Cellav Health and Aesthetics Ltd.</strong> (“Cellav”), has completed the development and U.S. cosmetic http://www.streetinsider.com/Globe+Newswire/Pluri+Advances+Toward+U.S.+Commercial+Launch+Through+Its+Subsidiary+Cellav%2C+Following+Completion+of+Regenerative+Aesthetic+Products+Listing/26587442.html Tue, 02 Jun 2026 07:30:00 -0400 A.06822034 A.50216147 O.06192945 O.20026344 O.31500450 PLUR PLUR http://www.streetinsider.com/Globe+Newswire/Pluri+Advances+Toward+U.S.+Commercial+Launch+Through+Its+Subsidiary+Cellav%2C+Following+Completion+of+Regenerative+Aesthetic+Products+Listing/26587442.html <p align="center"><strong>Two regenerative aesthetic and longevity products, with clinically validated ingredients</strong><strong>, are</strong><strong> expected to reach the U.S. market during 2026,</strong> <strong>entering a rapidly expanding U.S. medical aesthetics market, projected to reach </strong><a target="_blank" href="https://www.globenewswire.com/Tracker?data=rsSZU8I6FfWdsc-7NWbEmjP0fDuaQp5GWQolfeicHTShQ3DihqYOQIyswCp4R8wypniSkaqu_dDmlBcbKyoLY8zauCXcN5tEfnPvC31XsTfHRSwN5DQjmbTB7MM2zT2JY-XriiB_okHx1xE1y6zSkq4S85t5n_jxPq3L_HER5qg-rXMHwksxY3xA5NxRgAQH3i3XU1P72gfcdA9ypqaLGMddEDfHJqOmPd3wr1lemw85un0K37N33SFstwKhb87B-IuQzGByNgye8tkkzuLCqOFi5mJrWqNvGJQEUVrkcWx2W3nS0N01qTo5klvoGWZMAfiVicvF9UvYCh_4_zx_isERSwnhrFz3BvK67JO3toXaE1FJTqzRkZogyTfFERrkH_H14Qv42JBTyApFlF-io4J9vmAx3i4s6hrkL7P8v--ivT0BJGDehjyua1dc8DDcSshy46xkfk4hrtQETcOfOuIbosGDtYuRLzilNqtjKCENm9B6BVhyvKeOajoKcx7hzZYUZ5wLUTwPLs2W6pS1T8C2F6pZtTR-6yUyzFD_0qJtgKAki0u5BwGfaXbwVGJQjeSdlVkAAWBRpcW7UREeenadJrWOnTrIlIuUc0a0qu4GMMq0Co3an43pgXxb-B7UDKD7m9QR0HyW3Uu8UiGblg9z5UDZKwOUPVwAAwgfNhtThT66od0qxwA3sykqP3L1" rel="nofollow" target="_blank"><strong>$90</strong></a><strong> billion by 2030</strong></p> <p align="justify">HAIFA, Israel, June 02, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=jM8VeXIVTEh27XE4fGWuIfAowcsDLD5V3Rx4ZbfB0DCMv4tLTg6PopPRU3Mfyc4Dfu4IHex_sWd4vsI3IP5fZQ==" rel="nofollow" target="_blank">Pluri Inc</a>. (NASDAQ: PLUR) (TASE: PLUR), a biotechnology company pioneering 3D cell-expansion technology to power scalable cell-based products across therapeutics, regenerative aesthetics, longevity and agri-food tech, today announced that its consumer-health and aesthetics subsidiary, <strong>Cellav Health and Aesthetics Ltd.</strong> (“Cellav”), has completed the development and U.S. cosmetic http://www.streetinsider.com/Globe+Newswire/Pluri+Advances+Toward+U.S.+Commercial+Launch+Through+Its+Subsidiary+Cellav%2C+Following+Completion+of+Regenerative+Aesthetic+Products+Listing/26587442.html Tue, 02 Jun 2026 07:30:00 -0400 A.06822034 A.50216147 O.06192945 O.20026344 O.31500450 PLUR PLUR http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Pluri+Inc.++++++++++++++++For%3A+May+28/26583566.html si-local-file:///var/storage/secattach/20260601/26583566.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Pluri+Inc.++++++++++++++++For%3A+May+28/26583566.html Mon, 01 Jun 2026 16:08:00 -0400 O.31500450 PLUR http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Pluri+Inc.++++++++++++++++For%3A+May+28/26583566.html si-local-file:///var/storage/secattach/20260601/26583566.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Pluri+Inc.++++++++++++++++For%3A+May+28/26583566.html Mon, 01 Jun 2026 16:08:00 -0400 O.31500450 PLUR